Real Time Insider Transaction Data
Real Time Insider buys and sells Data - Insider Trades - Insider Transactions - Insider Trading Data - SEC Form 4 Data
Total | Transactions | Amount |
Buys | 0 | $0 |
Sells | 182 | $100,108,792 |
Security | Reporting Name | Relationship | Purchase/Sale | Shares | Price $ | D/I | ||||
28 Dec 2023 16:13 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 26 Dec 2023 | Sale | 68 | 57.8609 | 3,935 | D |
09 May 2024 17:15 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 May 2024 | Sale | 100 | 44.025 | 4,402 | D |
24 Oct 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 23 Oct 2023 | Sale | 131 | 46.0362 | 6,031 | D |
24 Oct 2023 16:20 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 23 Oct 2023 | Sale | 132 | 46.0362 | 6,077 | D |
11 Mar 2024 16:08 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Mar 2024 | Sale | 100 | 63.35 | 6,335 | D |
18 Mar 2024 16:19 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 15 Mar 2024 | Sale | 184 | 56.461 | 10,389 | D |
28 Dec 2023 16:13 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 27 Dec 2023 | Sale | 235 | 60.23 | 14,154 | D |
01 Dec 2023 16:11 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 30 Nov 2023 | Sale | 300 | 54.7866 | 16,436 | D |
31 Jan 2024 16:23 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 29 Jan 2024 | Sale | 279 | 64.1382 | 17,895 | D |
01 Sep 2023 16:08 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 31 Aug 2023 | Sale | 551 | 41.226 | 22,716 | D |
31 Jan 2024 16:28 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 29 Jan 2024 | Sale | 367 | 64.1382 | 23,539 | D |
31 Jan 2024 16:18 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 29 Jan 2024 | Sale | 367 | 64.1382 | 23,539 | D |
02 Dec 2022 16:30 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 01 Dec 2022 | Sale | 500 | 49.93 | 24,965 | D |
05 Jan 2023 19:40 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 03 Jan 2023 | Sale | 500 | 50.7 | 25,350 | D |
02 Feb 2023 16:15 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 01 Feb 2023 | Sale | 500 | 52.61 | 26,305 | D |
05 Mar 2024 16:07 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 01 Mar 2024 | Sale | 413 | 65.68 | 27,126 | D |
06 Jul 2023 16:16 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 03 Jul 2023 | Sale | 300 | 91.0983 | 27,329 | D |
17 Jan 2024 12:24 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 16 Jan 2024 | Sale | 438 | 66.8086 | 29,262 | D |
03 Nov 2022 16:28 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 01 Nov 2022 | Sale | 500 | 60.83 | 30,415 | D |
02 Mar 2023 16:20 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 01 Mar 2023 | Sale | 500 | 65.33 | 32,665 | D |
05 Apr 2023 16:54 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 03 Apr 2023 | Sale | 500 | 74.05 | 37,025 | D |
13 Feb 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 12 Feb 2024 | Sale | 597 | 67.7669 | 40,457 | D |
31 Jan 2023 16:51 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 30 Jan 2023 | Sale | 883 | 52.76 | 46,587 | D |
31 Jan 2023 16:47 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 30 Jan 2023 | Sale | 883 | 52.76 | 46,587 | D |
13 Feb 2024 17:06 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 12 Feb 2024 | Sale | 781 | 67.7669 | 52,926 | D |
31 Jan 2024 16:31 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 29 Jan 2024 | Sale | 835 | 64.1382 | 53,555 | D |
31 Jan 2024 16:21 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 29 Jan 2024 | Sale | 874 | 64.1382 | 56,057 | D |
19 Sep 2023 17:05 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 18 Sep 2023 | Sale | 1,250 | 45 | 56,250 | D |
18 Sep 2023 16:24 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Sep 2023 | Sale | 1,250 | 45.34 | 56,675 | D |
17 Jan 2024 16:45 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 16 Jan 2024 | Sale | 864 | 66.8086 | 57,723 | D |
31 Jan 2024 16:28 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 30 Jan 2024 | Sale | 883 | 65.53 | 57,863 | D |
18 Jul 2022 17:29 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Jul 2022 | Sale | 1,250 | 46.33 | 57,912 | D |
31 Jan 2024 16:36 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
31 Jan 2024 16:38 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
31 Jan 2024 16:34 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 29 Jan 2024 | Sale | 906 | 64.1382 | 58,109 | D |
20 Nov 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Nov 2023 | Sale | 1,250 | 47.74 | 59,675 | D |
17 Nov 2022 16:33 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Nov 2022 | Sale | 1,250 | 48.01 | 60,012 | D |
18 Oct 2023 17:43 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Oct 2023 | Sale | 1,250 | 48.5 | 60,625 | D |
29 Jun 2022 16:18 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 27 Jun 2022 | Sale | 1,341 | 46.7881 | 62,743 | I |
31 Jan 2024 16:23 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 30 Jan 2024 | Sale | 971 | 65.53 | 63,630 | D |
19 Dec 2022 16:37 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Dec 2022 | Sale | 1,250 | 52.35 | 65,438 | D |
21 Feb 2023 16:22 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Feb 2023 | Sale | 1,250 | 52.38 | 65,475 | D |
19 Jan 2023 16:55 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Jan 2023 | Sale | 1,250 | 52.42 | 65,525 | D |
21 Jun 2024 19:34 | APLS | Apellis Pharmaceuticals Inc | DUNLOP A. SINCLAIR | Director | 21 Jun 2024 | Sale | 1,695 | 39.63 | 67,173 | I |
23 Jan 2024 18:00 | APLS | Apellis Pharmaceuticals Inc | CHOPAS JAMES GEORGE | VP/Chief Accounting Officer | 22 Jan 2024 | Sale | 1,061 | 64.996 | 68,961 | D |
17 Oct 2022 17:57 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 14 Oct 2022 | Sale | 1,250 | 59.31 | 74,138 | D |
07 Sep 2023 16:08 | APLS | Apellis Pharmaceuticals Inc | SCHEIBLER LUKAS | Chief Research Officer | 06 Sep 2023 | Sale | 1,756 | 43.01 | 75,526 | D |
27 Feb 2023 16:32 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 23 Feb 2023 | Sale | 1,104 | 68.76 | 75,911 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 934 | 83.1711 | 77,682 | D |
13 Feb 2024 17:05 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 12 Feb 2024 | Sale | 1,148 | 67.7669 | 77,796 | D |
13 Feb 2024 16:43 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 12 Feb 2024 | Sale | 1,148 | 67.7669 | 77,796 | D |
21 Mar 2023 16:35 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Mar 2023 | Sale | 1,250 | 64.03 | 80,038 | D |
18 Jul 2023 16:40 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Jul 2023 | Sale | 1,250 | 64.79 | 80,988 | D |
16 Sep 2022 16:03 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Sep 2022 | Sale | 1,250 | 66 | 82,500 | D |
16 Aug 2022 17:00 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 15 Aug 2022 | Sale | 1,250 | 67.21 | 84,012 | D |
23 Jan 2024 18:01 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 22 Jan 2024 | Sale | 1,384 | 64.996 | 89,954 | D |
20 Dec 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 19 Dec 2023 | Sale | 1,605 | 57.0041 | 91,492 | D |
13 Feb 2024 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 12 Feb 2024 | Sale | 1,431 | 67.7669 | 96,974 | D |
18 Apr 2023 16:30 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 Apr 2023 | Sale | 1,250 | 81.05 | 101,312 | D |
23 Jan 2024 18:05 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 22 Jan 2024 | Sale | 1,607 | 64.996 | 104,449 | D |
17 Jan 2024 16:41 | APLS | Apellis Pharmaceuticals Inc | DELONG MARK JEFFREY | Chief Business & Strat Officer | 16 Jan 2024 | Sale | 1,631 | 66.8086 | 108,965 | D |
17 Jan 2024 16:47 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 16 Jan 2024 | Sale | 1,632 | 66.8086 | 109,032 | D |
17 Jan 2024 16:43 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 16 Jan 2024 | Sale | 1,632 | 66.8086 | 109,032 | D |
21 Jun 2023 16:34 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 20 Jun 2023 | Sale | 1,250 | 88.41 | 110,512 | D |
18 May 2023 17:12 | APLS | Apellis Pharmaceuticals Inc | MACHIELS ALEC | Director | 17 May 2023 | Sale | 1,250 | 88.66 | 110,825 | D |
23 Jan 2024 18:07 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 22 Jan 2024 | Sale | 1,738 | 64.996 | 112,963 | D |
27 Feb 2023 16:34 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Feb 2023 | Sale | 1,646 | 68.76 | 113,179 | D |
09 Jan 2023 19:02 | APLS | Apellis Pharmaceuticals Inc | GROSSI FEDERICO | Chief Medical Officer | 05 Jan 2023 | Sale | 2,500 | 48.79 | 121,975 | D |
17 Jan 2024 16:40 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 16 Jan 2024 | Sale | 1,857 | 66.8086 | 124,064 | D |
02 Dec 2022 16:30 | APLS | Apellis Pharmaceuticals Inc | GROSSI FEDERICO | Chief Medical Officer | 01 Dec 2022 | Sale | 2,500 | 49.93 | 124,825 | D |
05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 2,000 | 63.95 | 127,900 | D |
20 Dec 2023 16:18 | APLS | Apellis Pharmaceuticals Inc | WATSON DAVID O. | General Counsel | 19 Dec 2023 | Sale | 2,300 | 57.3827 | 131,980 | D |
02 Aug 2022 16:18 | APLS | Apellis Pharmaceuticals Inc | GROSSI FEDERICO | CHIEF MEDICAL OFFICER | 01 Aug 2022 | Sale | 2,500 | 55.99 | 139,975 | D |
06 Jun 2023 16:59 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 05 Jun 2023 | Sale | 1,600 | 90.6044 | 144,967 | D |
17 Jan 2024 16:36 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 16 Jan 2024 | Sale | 2,235 | 66.8086 | 149,317 | D |
17 Jan 2024 16:37 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 16 Jan 2024 | Sale | 2,235 | 66.8086 | 149,317 | D |
02 Sep 2022 16:22 | APLS | Apellis Pharmaceuticals Inc | GROSSI FEDERICO | CHIEF MEDICAL OFFICER | 01 Sep 2022 | Sale | 2,500 | 60.3 | 150,750 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 1,800 | 83.845 | 150,921 | D |
03 Nov 2022 16:27 | APLS | Apellis Pharmaceuticals Inc | GROSSI FEDERICO | Chief Medical Officer | 01 Nov 2022 | Sale | 2,500 | 60.83 | 152,075 | D |
25 Jan 2023 16:17 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 23 Jan 2023 | Sale | 2,955 | 51.58 | 152,419 | D |
05 Jan 2024 16:14 | APLS | Apellis Pharmaceuticals Inc | BAUMAL CAROLINE | Chief Medical Officer | 04 Jan 2024 | Sale | 2,751 | 60.0534 | 165,207 | D |
05 Oct 2022 17:14 | APLS | Apellis Pharmaceuticals Inc | GROSSI FEDERICO | CHIEF MEDICAL OFFICER | 03 Oct 2022 | Sale | 2,500 | 66.69 | 166,725 | D |
23 Jan 2024 18:11 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 22 Jan 2024 | Sale | 2,593 | 64.996 | 168,535 | D |
31 Jan 2024 16:26 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 29 Jan 2024 | Sale | 2,843 | 64.1382 | 182,345 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 2,120 | 87.6739 | 185,869 | D |
21 Dec 2022 16:13 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 19 Dec 2022 | Sale | 3,751 | 51.9678 | 194,931 | D |
14 Mar 2024 16:17 | APLS | Apellis Pharmaceuticals Inc | NICHOLSON NUR | Chief Technical Officer | 13 Mar 2024 | Sale | 3,452 | 58.1335 | 200,677 | D |
18 Jan 2024 16:54 | APLS | Apellis Pharmaceuticals Inc | LEWIS KAREN | Chief People Officer | 17 Jan 2024 | Sale | 3,276 | 65.58 | 214,840 | D |
23 Jan 2024 18:15 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 22 Jan 2024 | Sale | 3,413 | 64.996 | 221,831 | D |
23 Jan 2024 18:13 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 22 Jan 2024 | Sale | 3,551 | 64.996 | 230,801 | D |
25 Jan 2023 16:14 | APLS | Apellis Pharmaceuticals Inc | EISELE JEFFREY | Chief Development Officer | 23 Jan 2023 | Sale | 4,479 | 51.58 | 231,027 | D |
02 Apr 2024 16:06 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Apr 2024 | Sale | 4,000 | 58.66 | 234,640 | D |
12 Jul 2022 17:55 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 11 Jul 2022 | Sale | 5,000 | 48.42 | 242,100 | D |
21 Nov 2023 17:36 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 21 Nov 2023 | Sale | 5,000 | 48.8 | 244,000 | D |
05 Mar 2024 16:04 | APLS | Apellis Pharmaceuticals Inc | SULLIVAN TIMOTHY EUGENE | Chief Financial Officer | 01 Mar 2024 | Sale | 4,000 | 62.86 | 251,440 | D |
07 Dec 2022 08:30 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 05 Dec 2022 | Sale | 5,000 | 50.38 | 251,900 | D |
05 Jan 2023 20:00 | APLS | Apellis Pharmaceuticals Inc | TOWNSEND ADAM J. | Chief Commercial Officer | 03 Jan 2023 | Sale | 5,000 | 50.7 | 253,500 | D |
23 Jan 2024 18:03 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 22 Jan 2024 | Sale | 3,913 | 64.996 | 254,329 | D |
18 May 2023 17:10 | APLS | Apellis Pharmaceuticals Inc | FRANCOIS CEDRIC | Chief Executive Officer | 16 May 2023 | Sale | 3,007 | 85.9012 | 258,305 | D |
09 Apr 2024 16:25 | APLS | Apellis Pharmaceuticals Inc | DESCHATELETS PASCAL | Chief Scientific Officer | 08 Apr 2024 | Sale | 4,728 | 54.9152 | 259,639 | D |
* D/I = Direct / Indirect
* 10% = Entity with 10% or higher ownership stake
* A = Amendment Filing (SEC Form 4/A)